RPL17 and head and neck squamous cell carcinoma: Preliminary findings from clinical trials have also suggested that neoadjuvant treatment incorporating PD - 1 inhibitors with TP + CETUX can induce a high pathological tumor regression rate in LA - HNSCC (15–18).